WEST VIRGINIA LEGISLATURE

2018 REGULAR SESSION

Introduced

House Bill 4336

BY DELEGATES ELLINGTON, SUMMERS, ROHRBACH,

HOUSEHOLDER, ATKINSON, CRISS, HOLLEN, HILL,

ROWAN, DEAN AND COOPER

[Introduced January 26, 2018; Referred

to the Committee on Prevention and Treatment of

Substance Abuse then the Judiciary.]

A BILL to amend and reenact §60A-2-204, §60A-2-206, §60A-2-210 and §60A-2-212 of the Code
 of West Virginia, 1931, as amended, all relating to updating the schedule of controlled
 substances.

Be it enacted by the Legislature of West Virginia:

ARTICLE 2. STANDARDS AND SCHEDULES.

§60A-2-204. Schedule I.

1 (a) Schedule I shall consist of the drugs and other substances, by whatever official name, 2 common or usual name, chemical name, or brand name designated, listed in this section including 3 their isomers, esters, ethers, salts and salts of isomers, esters and ethers, whenever the existence 4 of such isomers, esters, ethers and salts is possible within the specific chemical designation. 5 (b) Opiates. Unless specifically excepted or unless listed in another schedule, any of the 6 following opiates, including their isomers, esters, ethers, salts and salts of isomers, esters and ethers, whenever the existence of such isomers, esters, ethers and salts is possible within the 7 8 specific chemical designation (for purposes of subdivision (34) of this subsection only, the term 9 isomer includes the optical and geometric isomers): 10 (N-[1-(1-methyl-2-phenethyl) (1) Acetyl-alpha-methylfentanyl -4-piperidinyl]--11 phenylacetamide); 12 (2) Acetylmethadol; 13 (3) Allylprodine: 14 (4) Alphacetylmethadol (except levoalphacetylmethadol also known as levo-alpha-acetylmethadol, 15 levomethadyl acetate, or LAAM); 16 (5) Alphameprodine; 17 (6) Alphamethadol; 18 (7)Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl) ethyl-4-piperidyl] 19 propionanilide; 1-(1-methyl-2-phenylethyl)-4-(- propanilido) piperidine); 20 (8) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl) ethyl- 4-piperidinyl]--phenylpropanamide);

21

(9) Benzethidine;

- 22 (10) Betacetylmethadol;
- 23 (11) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl) -4- piperidinyl]-N-phenylpropanamide);
- 24 (12) Beta-hydroxy-3-methylfentanyl (other name: N-[1-(2- hydroxy-2-phenethyl)-3-methyl-
- 25 4-piperidinyl]-N-phenylpropanamide);
- 26 (13) Betameprodine;
- 27 (14) Betamethadol;
- 28 (15) Betaprodine;
- 29 (16) Clonitazene;
- 30 (17) Dextromoramide;
- 31 (18) Diampromide;
- 32 (19) Diethylthiambutene;
- 33 (20) Difenoxin;
- 34 (21) Dimenoxadol;
- 35 (22) Dimepheptanol;
- 36 (23) Dimethylthiambutene;
- 37 (24) Dioxaphetyl butyrate;
- 38 (25) Dipipanone;
- 39 (26) Ethylmethylthiambutene;
- 40 (27) Etonitazene;
- 41 (28) Etoxeridine;
- 42 (29) Furethidine;
- 43 (30) Hydroxypethidine;
- 44 (31) Ketobemidone;
- 45 (32) Levomoramide;
- 46 (33) Levophenacylmorphan;

- 47 (34) 3-Methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4- piperidyl]-N-phenylpropanamide);
- 48 (35) 3-methylthiofentanyl (N-[3-methyl-1-(2-thienyl) ethyl-4- piperidinyl]--phenylpropanamide);
- 49 (36) Morpheridine;
- 50 (37) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
- 51 (38) Noracymethadol;
- 52 (39) Norlevorphanol;
- 53 (40) Normethadone;
- 54 (41) Norpipanone;
- 55 (42) Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4-piperidinyl] propanamide);
- 56 (43) PEPAP(1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);
- 57 (44) Phenadoxone;
- 58 (45) Phenampromide;
- 59 (46) Phenomorphan;
- 60 (47) Phenoperidine;
- 61 (48) Piritramide;
- 62 (49) Proheptazine;
- 63 (50) Properidine;
- 64 (51) Propiram;
- 65 (52) Racemoramide;
- 66 (53) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4- piperidinyl]-propanamide);
- 67 (54) Tilidine;
- 68 (55) Trimeperidine.
- 69 (c) Opium derivatives: -- Unless specifically excepted or unless listed in another schedule,

70 any of the following opium immediate derivatives, its salts, isomers and salts of isomers whenever

71 the existence of such salts, isomers and salts of isomers is possible within the specific chemical

72 designation:

73	(1) Acetorphine;
74	(2) Acetyldihydrocodeine;
75	(3) Benzylmorphine;
76	(4) Codeine methylbromide;
77	(5) Codeine-N-Oxide;
78	(6) Cyprenorphine;
79	(7) Desomorphine;
80	(8) Dihydromorphine;
81	(9) Drotebanol;
82	(10) Etorphine (except HCI Salt);
83	(11) Heroin;
84	(12) Hydromorphinol;
85	(13) Methyldesorphine;
86	(14) Methyldihydromorphine;
87	(15) Morphine methylbromide;
88	(16) Morphine methylsulfonate;
89	(17) Morphine-N-Oxide;
90	(18) Myrophine;
91	(19) Nicocodeine;
92	(20) Nicomorphine;
93	(21) Normorphine;
94	(22) Pholcodine;
95	(23) Thebacon.
96	(d) Hallucinogenic substances Unless specifically excepted or unless listed in another
97	schedule, any material, compound, mixture or preparation, which contains any quantity of the

98 following hallucinogenic substances, or which contains any of its salts, isomers and salts of

2018R2250

- 99 isomers, whenever the existence of such salts, isomers, and salts of isomers is possible within
- 100 the specific chemical designation (for purposes of this subsection only, the term "isomer" includes

101 the optical, position and geometric isomers):

- 102 (1) Alpha-ethyltryptamine; some trade or other names: etryptamine; Monase; alpha-ethy 103 1H-indole-3-ethanamine; 3-(2- aminobutyl) indole; alpha-ET; and AET;
- 104 (2) 4-bromo-2, 5-dimethoxy-amphetamine; some trade or other names: 4-bromo-2,5 105 dimethoxy-alpha-methylphenethylamine; 4-bromo- 2,5-DMA;
- 106 (3) 4-Bromo-2,5-dimethoxyphenethylamine; some trade or other names: 2-(4-bromo-2,5-

107 dimethoxyphenyl)-1-aminoethane; alpha- desmethyl DOB; 2C-B, Nexus;

- 108 (4)(A) N-(2-Methoxybenzyl)-4-bromo-2, 5-dimethoxyphenethylamine. The substance has
 109 the acronym 25B-NBOMe.
- 110 (B) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25C-NBOMe)
- 111 (C) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25I-NBOMe)
- 112 (5) 2,5-dimethoxyamphetamine; some trade or other names: 2,5-dimethoxy-alpha-
- 113 methylphenethylamine; 2,5-DMA;
- 114 (6) 2,5-dimethoxy-4-ethylamphet-amine; some trade or other names: DOET;
- 115 (7) 2,5-dimethoxy-4-(n)-propylthiophenethylamine (other name: 2C-T-7);
- 116 (8) 4-methoxyamphetamine; some trade or other names: 4-methoxy-alpha 117 methylphenethylamine; paramethoxyamphetamine; PMA;
- 118 (9) 5-methoxy-3, 4-methylenedioxy-amphetamine;
- 119 (10) 4-methyl-2,5-dimethoxy-amphetamine; some trade and other names: 4-methyl-2,5-
- 120 dimethoxy-alpha-methylphenethylamine; "DOM"; and "STP";
- 121 (11) 3,4-methylenedioxy amphetamine;
- 122 (12) 3,4-methylenedioxymethamphetamine (MDMA);
- 123 (13) 3,4-methylenedioxy-N-ethylamphetamine (also known as ethyl-alpha-methyl-3,4
- 124 (methylenedioxy) phenethylamine, N-ethyl MDA, MDE, MDEA);

125 (14) N-hydroxy-3,4-methylenedioxyamphetamine (also known as – hydroxy-alpha-methyl-

126 3,4 (methylenedioxy) phenethylamine, and – hydroxy MDA);

127 (15) 3,4,5-trimethoxy amphetamine;

128 (15) (16) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);

129 (17) Alpha-methyltryptamine (other name: AMT);

130 (18) Bufotenine; some trade and other names: 3-(beta-Dimethylaminoethyl)-5-

131 hydroxyindole;3-(2-dimethylaminoethyl) -5-indolol; N, N-dimethylserotonin; 5-hydroxy-N,N-

132 dimethyltryptamine; mappine;

133 (19) Diethyltryptamine; sometrade and other names: N, N-Diethyltryptamine; DET;

134 (20) Dimethyltryptamine; some trade or other names: DMT;

135 (21) 5-Methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT);

136 (22) Ibogaine; some trade and other names: 7-Ethyl-6, 6 Beta, 7, 8, 9, 10, 12, 13-

137 octahydro-2-methoxy-6, 9-methano-5H- pyrido [1', 2': 1, 2] azepino [5,4-b] indole; Tabernanthe

138 iboga;

139 (23) Lysergic acid diethylamide;

140 (24) Marihuana;

141 (25) Mescaline;

142 (26) Parahexyl-7374; some trade or other names: 3-Hexyl -1-hydroxy-7, 8, 9, 10 143 tetrahydro-6, 6, 9-trimethyl-6H-dibenzo [b,d] pyran; Synhexyl;

144 (27) Peyote; meaning all parts of the plant presently classified botanically as Lophophora
145 williamsii Lemaire, whether growing or not, the seeds thereof, any extract from any part of such
146 plant, and every compound, manufacture, salts, immediate derivative, mixture or preparation of
147 such plant, its seeds or extracts;

148 (28) N-ethyl-3-piperidyl benzilate;

149 (29) N-methyl-3-piperidyl benzilate;

150 (30) Psilocybin;

2018R2250

151

(31) Psilocyn;

152 (32) Tetrahydrocannabinols; synthetic equivalents of the substances contained in the 153 plant, or in the resinous extractives of Cannabis, sp. and/or synthetic substances, immediate 154 derivatives and their isomers with similar chemical structure and pharmacological activity such as 155 the following:

delta-1 Cis or trans tetrahydrocannabinol, and their optical isomers;

157 delta-6 Cis or trans tetrahydrocannabinol, and their optical isomers;

delta-3,4 Cis or trans tetrahydrocannabinol, and its optical isomers;

159 (Since nomenclature of these substances is not internationally standardized, compounds
160 of these structures, regardless of numerical designation of atomic positions covered.)

161 (33) Ethylamine analog of phencyclidine; some trade or other names: N-ethyl-1-162 phenylcyclohexylamine, (1-phenylcyclohexyl) ethylamine, N-(1-phenylcyclohexyl) ethylamine, 163 cyclohexamine, PCE;

164 (34) Pyrrolidine analog of phencyclidine; some trade or other names: 1-(1-165 phenylcyclohexyl)-pyrrolidine, PCPy, PHP;

166 (35) Thiophene analog of phencyclidine; some trade or other names: 1-[1-(2-thienyl) 167 cyclohexyl]-piperidine, 2-thienylanalog of phencyclidine; TPCP, TCP;

168 (36) 1[1-(2-thienyl)cyclohexyl]pyrroldine; some other names: TCPy.

169 (37) 4-methylmethcathinone (Mephedrone);

170 (38) 3,4-methylenedioxypyrovalerone (MDPV);

- 171 (39) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E);
- 172 (40) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D)
- 173 (41) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C)
- 174 (42) 2-(4-lodo-2,5-dimethoxyphenyl)ethanamine (2C-l)
- 175 (43) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2)
- 176 (44) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4)

2018R2250

177 (45) 2-(2.5-Dimethoxyphenyl)ethanamine (2C-H) 178 (46) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N) 179 (47) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P) 180 (48) 3,4-Methylenedioxy-N-methylcathinone (Methylone) 181 (49) 2,5-dimethoxy-4-(n)-propyltghiophenethylamine (2C-T-7, itsoptical isomers, salts and 182 salts of isomers 183 (50) 5-methoxy-N,N-dimethyltryptamine some trade or other names: 5-methoxy-3-[2-184 (dimethylamino)ethyl]indole; 5-MeO-DMT(5-MeO-DMT) 185 (51) Alpha-methyltryptamine (other name: AMT) 186 (52) 5-methoxy-N,N-diisopropyltryptamine (other name: 5-MeO-DIPT) 187 (53) Synthetic Cannabinoids as follows: 188 (A) 2-[(1R,3S)-3-hydroxycyclohexyl]-5- (2-methyloctan-2-yl)phenol) {also known as CP 189 47,497 and homologues}; 190 (B) rel-2-[(1S,3R)-3-hydroxycyclohexyl] -5-(2-methylnonan-2-yl)phenol {also known as CP 191 47,497-C8 homolog}; 192 (C) [(6aR)-9-(hydroxymethyl)-6, 6-dimethyl-3-(2-methyloctan-2-yl)-6a, 7,10,10a-193 tetrahydrobenzo[c]chromen-1-ol)] {also known as HU-210}; 194 (D) (dexanabinol); 195 (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-196 tetrahydrobenzol[c]chromen-1-ol) {also known as HU-211}; 197 (E) 1-Pentyl-3-(1-naphthoyl)indole {also known as JWH-018}; 198 (F) 1-Butyl-3-(1-naphthoyl)indole {also known as JWH-073}; 199 (G) (2-methyl-1-propyl-1H-indol-3-yl)-1-napthalenyl-methanone {also known as JWH-200 015}; 201 (H) (1-hexyl-1H-indol-3-yl)-1-naphthalenyl-methanone {also known as JWH-019}: 202 (I) [1-[2-(4-morpholinyl) ethyl] -1H-indol-3-yl]-1-naphthalenyl-methanone {also known as

2018R2250

203	JWH-200};
204	(J) 1-(1-pentyl-1H-indol-3-yl)-2-(3-hydroxyphenyl)-ethanone {also known as JWH-250};
205	(K) 2-((1S,2S,5S)-5-hydroxy-2- (3-hydroxtpropyl)cyclohexyl) -5-(2-methyloctan-2-
206	yl)phenol {also known as CP 55,940};
207	(L) (4-methyl-1-naphthalenyl) (1-pentyl-1H-indol-3-yl) -methanone {also known as JWH-
208	122};
209	(M) (4-methyl-1-naphthalenyl) (1-pentyl-1H-indol-3-yl) -methanone {also known as JWH-
210	398;
211	(N) (4-methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone {also known as RCS-4};
212	(O) 1-(1-(2-cyclohexylethyl) -1H-indol-3-yl) -2-(2-methoxyphenyl) ethanone {also known
213	as RCS-8};
214	(P) 1-pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081);
215	(Q) 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM2201); and
216	(R) 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM694).
217	(54) Synthetic cannabinoids: or any material, compound, mixture or preparation which
218	contains any quantity of the following substances, including their analogues, congeners,
219	homologues, isomers, salts and salts of analogues, congeners, homologues and isomers, as
220	follows:
221	(A) CP 47,497 AND homologues, 2-[(1R,3S)-3-Hydroxycyclohexyl]-5-(2-methyloctan-2-
222	YL)phenol);
223	(B) HU-210, [(6AR,10AR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-Methyloctan-2-YL)-
224	6A,7,10, 10A-tetrahydrobenzo[C] chromen-1-OL)];
225	(C) HU-211, (dexanabinol, (6AS,10AS)-9-(hydroxymethyl)-6,6-Dimethyl-3-(2-
226	methyloctan-2-YL)-6A,7,10,10atetrahydrobenzo[C]chromen-1-OL);
227	(D) JWH-018, 1-pentyl-3-(1-naphthoyl)indole;
228	(E) JWH-019, 1-hexyl-3-(1-naphthoyl)indole;

2018R2250

229	(F) JWH-073, 1-butyl-3-(1-naphthoyl)indole;
230	(G) JWH-200, (1-(2-morpholin-4-ylethyl)indol-3-yl)- Naphthalen-1-ylmethanone;
231	(H) JWH-250, 1-pentyl-3-(2-methoxyphenylacetyl)indole.]
232	Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate (5F-
233	<u>ADB);</u>
234	Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate (5F-AMB);
235	Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate (FUB-
236	<u>AMB);</u>
237	N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (5F-APINACA);
238	N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide
239	(ADB-FUBINACA);
240	Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate
241	(MDMB-CHMICA):
242	Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate
243	(MDMB-FUBINACA);
244	(55) Synthetic cannabinoids including any material, compound, mixture or preparation that
245	is not listed as a controlled substance in Schedule I through V, is not a federal Food and Drug
245 246	is not listed as a controlled substance in Schedule I through V, is not a federal Food and Drug Administration approved drug or used within legitimate and approved medical research and which
246	Administration approved drug or used within legitimate and approved medical research and which
246 247	Administration approved drug or used within legitimate and approved medical research and which contains any quantity of the following substances, their salts, isomers, whether optical positional
246 247 248	Administration approved drug or used within legitimate and approved medical research and which contains any quantity of the following substances, their salts, isomers, whether optical positional or geometric, analogues, homologues and salts of isomers, analogues and homologues, unless
246 247 248 249	Administration approved drug or used within legitimate and approved medical research and which contains any quantity of the following substances, their salts, isomers, whether optical positional or geometric, analogues, homologues and salts of isomers, analogues and homologues, unless specifically exempted, whenever the existence of these salts, isomers, analogues, homologues
246 247 248 249 250	Administration approved drug or used within legitimate and approved medical research and which contains any quantity of the following substances, their salts, isomers, whether optical positional or geometric, analogues, homologues and salts of isomers, analogues and homologues, unless specifically exempted, whenever the existence of these salts, isomers, analogues, homologues and salts of isomers, analogues and homologues if possible within the specific chemical
246 247 248 249 250 251	Administration approved drug or used within legitimate and approved medical research and which contains any quantity of the following substances, their salts, isomers, whether optical positional or geometric, analogues, homologues and salts of isomers, analogues and homologues, unless specifically exempted, whenever the existence of these salts, isomers, analogues, homologues and salts of isomers, analogues and homologues if possible within the specific chemical designation:
246 247 248 249 250 251 252	Administration approved drug or used within legitimate and approved medical research and which contains any quantity of the following substances, their salts, isomers, whether optical positional or geometric, analogues, homologues and salts of isomers, analogues and homologues, unless specifically exempted, whenever the existence of these salts, isomers, analogues, homologues and salts of isomers, analogues and homologues if possible within the specific chemical designation: (A) Tetrahydrocannabinols: meaning tetrahydrocannabinols which are naturally contained

2018R2250

INTRODUCED

255	isomers with analogous chemical structure and or pharmacological activity such as the following:
256	(i) DELTA-1 CIS OR trans tetrahydrocannabinol and their Optical isomers.
257	(ii) DELTA-6 CIS OR trans tetrahydrocannabinol and their optical isomers.
258	(iii) DELTA-3,4 CIS or their trans tetrahydrocannabinol and their optical isomers.
259	(56) Synthetic Phenethylamines (including their optical, positional, and geometric isomers,
260	salts and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers):
261	(A) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe/ 2C-I-
262	NBOMe);
263	(B) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe/2C-
264	C-NBOMe);
265	(C) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe/
266	2C-B-NBOMe);
267	(57) Synthetic Opioids (icluding their isomers, esters, ethers, salts and salts of isomers,
268	esters and ethers):
269	(A) N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide (acetyl fentanyl);
270	(B) furanyl fentanyl;
271	(C) 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (also known as U-
272	47700);
273	(D) N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide, also known as N-(1-
274	phenethylpiperidin-4-yl)-N-phenylbutanamide, (butyryl fentanyl);
275	(E) N-[1-[2-hydroxy-2-(thiophen-2-yl)ethylpiperidin-4-yl]-N-phenylpropionamide, also
276	known as N-[1-[2-hydroxy-2-(2-thienyl)ethyl]-4-piperidinyl]-N-phenylpropanamide, (beta-
277	hydroxythiofentanyl).
278	N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide (acryl fentanyl)
279	N-(1-phenethylpiperidin-4-yl)-N-phenylisobutyramide (isobutyryl fentanyl)
280	N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide (cyclopropyl fentanyl)

2018R2250

281	2-(2,4-dichlorophenyl)-N-((1S,2S)-2-(dimethylamino)cyclohexyl)-N-methylacetamide
282	(also known as
283	<u>U-48800)</u>
284	Trans-3,4-dichloro-N-[2-(diethylamino)cyclohexyl]-N-methyl-benzamide (also known as
285	<u>U-49900)</u>
286	Trans-3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methyl-benzeneacetamide (also
287	known as
288	<u>U-51754)</u>
289	(58) Opioid Receptor Agonist (including its isomers, esters, ethers, salts, and salts of
290	isomers, esters and ethers):
291	(A) AH-7921 (3,4-dichloro-N- (1dimethylamino)cyclohexylmethyl]benzamide).
292	(B) Naphthoylindoles or any compound containing a 3-(-1- Napthoyl) indole structure with
293	substitution at the nitrogen atom of the indole ring whether or not further substituted in the indole
294	ring to any extent and whether or not substituted in the naphthyl ring to any extent. This shall
295	include the following:
296	(i) JWH 015;
297	(ii) JWH 018;
298	(iii) JWH 019;
299	(iv) JWH 073;
300	(v) JWH 081;
301	(vi) JWH 122;
302	(vii) JWH 200;
303	(viii) JWH 210;
304	(ix) JWH 398;
305	(x) AM 2201;

306 (xi) WIN 55,212.

2018R2250

307 (59) Naphylmethylindoles or any compound containing a 1hindol-3-yl-(1-naphthyl) 308 methane structure with a substition at the nitrogen atom of the indole ring whether or not further 309 substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to 310 any extent. This shall include, but not be limited to, JWH 175 and JWH 184.

311 (60) Naphthoylpyrroles or any compound containing a 3-(1- Naphthoyl) pyrrole structure 312 with substitution at the nitrogen atom of the pyrrole ring whether or not further substituted in the 313 pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent. This 314 shall include, but not be limited to, JWH 147 and JWH 307.

315 (61) Naphthylmethylindenes or any compound containing a Naphthylideneindene 316 structure with substitution at the 3- Position of the indene ring whether or not further substituted 317 in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent. 318 This shall include, but not be limited to, JWH 176.

319 (62) Phenylacetylindoles or any compound containing a 3- Phenylacetylindole structure 320 with substitution at the nitrogen atom of the indole ring whether or not further substituted in the 321 indole ring to any extent and whether or not substituted in the phenyl ring to any extent. This shall 322 include the following:

- 323 (A) RCS-8, SR-18 OR BTM-8;
- 324 (B) JWH 250;
- 325 (C) JWH 203;
- 326 (D) JWH 251;
- 327 (E) JWH 302.

328 (63) Cyclohexylphenols or any compound containing a 2-(3- hydroxycyclohexyl) phenol 329 structure with a substitution at the 5-position of the phenolic ring whether or not substituted in the 330 cyclohexyl ring to any extent. This shall include the following:

331 (A) CP 47,497 and its homologues and analogs;

332 (B) Cannabicyclohexanol;

2018R2250

333 (C) CP 55,940.

334 (64) Benzoylindoles or any compound containing a 3-(benzoyl) indole structure with 335 substitution at the nitrogren atom of the indole ring whether or not further substituted in the indole 336 ring to any extent and whether or not substituted in the phenyl ring to any extent. This shall include 337 the following:

- 338 (A) AM 694;
- 339 (B) Pravadoline WIN 48,098;
- 340 (C) RCS 4;
- 341 (D) AM 679.

342 (62) [2,3-dihydro-5 methyl-3-(4-morpholinylmethyl)pyrrolo [1,2,3-DE]-1, 4-benzoxazin-6 343 YL]-1-napthalenymethanone. This shall include WIN 55,212-2.

344 (65) Dibenzopyrans or any compound containing a 11-hydroxydelta 8-345 tetrahydrocannabinol structure with substitution on the 3-pentyl group. This shall include HU-210, 346 HU-211, JWH 051 and JWH 133.

347 (66) Adamantoylindoles or any compound containing a 3-(-1- Adamantoyl) indole structure
348 with substitution at the nitrogen atom of the indole ring whether or not further substituted in the
349 adamantoyl ring system to any extent. This shall include AM1248.

350 (67) Tetramethylcyclopropylindoles or any compound containing A 3-351 tetramethylcyclopropylindole structure with substitution at the nitrogen atom of the indole ring 352 whether or not further substituted in the indole ring to any extent and whether or not substituted 353 in the tetramethylcyclopropyl ring to any extent. This shall include UR-144 and XLR-11.

354 (68) N-(1-Adamantyl)-1-pentyl-1h-indazole-3-carboxamide. This shall include AKB48.

355 (69) Any other synthetic chemical compound that is a Cannabinoid receptor type 1 agonist 356 as demonstrated by binding studies and functional assays that is not listed in Schedules II, III, IV 357 and V, not federal Food and Drug Administration approved drug or used within legitimate, 358 approved medical research. Since nomenclature of these substances is not internationally

- 359 standardized, any immediate precursor or immediate derivative of these substances shall be360 covered.
- 361 (70) Tryptamines:
- 362 (A) 5- methoxy- N- methyl-N-isopropyltryptamine (5-MeO-MiPT)
- 363 (B) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT)
- 364 (C) 4-hydroxy-N-methyl-N-isopropyltryptamine (4-HO-MiPT)
- 365 (D) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET)
- 366 (E) 4-acetoxy-N,N-diisopropyltryptamine (4-AcO-DiPT)
- 367 (F) 5-methoxy- α -methyltryptamine (5-MeO-AMT)
- 368 (G) 4-methoxy-N,N-Dimethyltryptamine (4-MeO-DMT)
- 369 (H) 4-hydroxy Diethyltryptamine (4-HO-DET)
- 370 (I) 5- methoxy- N,N- diallyltryptamine (5-MeO-DALT)
- 371 (J) 4-acetoxy-N,N-Dimethyltryptamine (4-AcO DMT)
- 372 (K) 4-hydroxy Diethyltryptamine (4-HO-DET)
- 373 (e) Depressants. -- Unless specifically excepted or unless listed in another schedule, any
- 374 material, compound, mixture, or preparation which contains any quantity of the following
- 375 substances having a depressant effect on the central nervous system, including its salts, isomers
- 376 and salts of isomers whenever the existence of such salts, isomers and salts of isomers is
- 377 possible within the specific chemical designation:
- 378 (1) Mecloqualone;
- 379 (2) Methaqualone.
- (f) Stimulants. --- Unless specifically excepted or unless listed in another schedule, any
 material, compound, mixture, or preparation which contains any quantity of the following
 substances having a stimulant effect on the central nervous system, including its salts, isomers
 and salts of isomers:
- 384 (1) Aminorex; some other names: aminoxaphen; 2-amino-5- phenyl-2-oxazoline; or 4,5-

2018R2250

385

dihydro-5-phenyl-2-oxazolamine;

(2) Cathinone; some trade or other names: 2-amino-1-phenyl-1- propanone, alpha-386 387 aminopropiophenone, 2-aminopropiophenone and norephedrone;

388 (3) Fenethylline;

389 (4) Methcathinone, its immediate precursors and immediate derivatives, its salts, optical 390 isomers and salts of optical isomers; some other names: (2-(methylamino)-propiophenone; alpha-391 (methylamino)propiophenone; 2-(methylamino)-1-phenylpropan-1one; alpha---392 methylaminopropiophenone; monomethylpropion; 3,4-methylenedioxypyrovalerone and/or 393 mephedrone;3,4-methylenedioxypyrovalerone (MPVD); ephedrone; N-methylcathinone; 394 methylcathinone; AL-464; AL-422; AL- 463 and UR1432;

395 (+-) cis-4-methylaminorex; ((+-)cis-4.5-dihydro-4-methyl- 5-phenyl-2-oxazolamine);

396 (6) N-ethylamphetamine;

397 (7) N,N-dimethylamphetemine; also known as N,N-alpha- trimethyl-benzeneethanamine;

398 N,N-alpha-trimethylphenethylamine.

399 (8) Alpha-pyrrolidinopentiophenone, also known as alpha-PVP, optical isomers, salts and 400 salts of isomers.

- (9) Substituted amphetamines: 401
- 402 (A) 2-Fluoroamphetamine
- 403 (B) 3-Fluoroamphetamine
- 404 (C) 4-Fluoroamphetamine
- 405 (D) 2-chloroamphetamine
- 406 (E) 3-chloroamphetamine
- 407 (F) 4-chloroamphetamine
- 408 (G) 2-Fluoromethamphetamine
- 409 (H) 3-Fluoromethamphetamine
- 410 (I) 4-Fluoromethamphetamine

2018R2250

411	(J) 4-chloromethamphetamine
412	(g) Temporary listing of substances subject to emergency scheduling. Any material,
413	compound, mixture or preparation which contains any quantity of the following substances:
414	(1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl), its optical isomers,
415	salts, and salts of isomers.
416	(2) N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl), its optical
417	isomers, salts and salts of isomers.
418	(3) N-benzylpiperazine, also known as BZP.
419	(4) Cyclopentyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-
420	phenylcyclopentanecarboxamide);
421	(5) 4-fluorobutyryl fentanyl (N-(4-fluorophenyl)-N-[1-(2-phenylethyl)piperidin-4-yl]-
422	butyramide);
423	(6) Isobutyryl fentanyl (2-methyl-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]-
424	propanamide);
425	(7) Methoxyacetyl fentanyl (2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]-
426	acetamide);
427	(8) 3-methylbutyryl fentanyl (N-[3-methyl-1-(2-phenylethyl)piperidin-4-yl]-N-
428	phenylbutyramide);
429	(9) 4-methoxybutyryl fentanyl (N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-
430	yl)butyramide):
431	(10) Ocfentanil (N-(2-fluorophenyl)-2-methoxy-N-[1-(2-phenylethyl)piperidin-4-yl]-
432	acetamide);
433	(11) Tetrahydrofuran fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-
434	carboxamide);
435	(12) Valeryl fentanyl (N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]pentanamide).
436	(h) The following controlled substances are included in Schedule I:

2018R2250

437 (1) Synthetic Cathinones or any compound, except bupropion or compounds listed under
438 a different schedule, or compounds used within legitimate and approved medical research,
439 structurally derived from 2- Aminopropan-1-one by substitution at the 1-position with Monocyclic
440 or fused polycyclic ring systems, whether or not the compound is further modified in any of the
441 following ways:

442 (A) By substitution in the ring system to any extent with Alkyl, alkylenedioxy, alkoxy,
443 haloalkyl, hydroxyl or halide Substituents whether or not further substituted in the ring system by
444 one or more other univalent substituents.

445 (B) By substitution at the 3-position with an acyclic alkyl substituent.

446 (C) By substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl or 447 methoxybenzyl groups.

448 (D) By inclusion of the 2-amino nitrogen atom in a cyclic structure.

449 (2) Any other synthetic chemical compound that is a Cannabinoid receptor type 1 agonist
 450 as demonstrated by binding studies and functional assays that is not listed in Schedules II, III, IV
 451 and V, not federal Food and Drug Administration approved drug or used within legitimate,
 452 approved medical research.

§60A-2-206. Schedule II.

(a) Schedule II consists of the drugs and other substances, by whatever official name,
 common or usual name, chemical name or brand name designated, listed in this section.

3 (b) Substances, vegetable origin or chemical synthesis. -- Unless specifically excepted or
4 unless listed in another schedule, any of the following substances whether produced directly or
5 indirectly by extraction from substances of vegetable origin, or independently by means of
6 chemical synthesis, or by a combination of extraction and chemical synthesis:

7 (1) Opium and opiate, and any salt, compound, derivative or preparation of opium or opiate
8 excluding apomorphine, thebaine-derived butorphanol, dextrorphan, nalbuphine, nalmefene,
9 naloxone and naltrexone, and their respective salts, but including the following:

- 10 (A) Raw opium;
- 11 (B) Opium extracts;
- 12 (C) Opium fluid;
- 13 (D) Powdered opium;
- 14 (E) Granulated opium;
- 15 (F) Tincture of opium;
- 16 (G) Codeine;
- 17 (H) Dihydroetorphine;
- 18 (I) Ethylmorphine;
- 19 (J) Etorphine hydrochloride;
- 20 (K) Hydrocodone;
- 21 (L) Hydromorphone;
- 22 (M) Metopon;
- 23 (N) Morphine;
- 24 (O) Oripavine;
- 25 (P) Oxycodone;
- 26 (Q) Oxymorphone; and
- 27 (R) Thebaine;

(2) Any salt, compound, derivative or preparation thereof which is chemically equivalent
 or identical with any of the substances referred to in subdivision (1) of this subsection, except that
 these substances shall not include the isoquinoline alkaloids of opium;

31 (3) Opium poppy and poppy straw;

32 (4) Coca leaves and any salt, compound, derivative or preparation of coca leaves 33 (including cocaine and ecgonine and their salts, isomers, derivatives and salts of isomers and 34 derivatives), and any salt, compound, derivative or preparation thereof which is chemically 35 equivalent or identical with any of these substances, except that the substances shall not include

2018R2250

decocainized coca leaves or extractions of coca leaves, which extractions do not contain cocaine
or ecgonine;

38 (5) Concentrate of poppy straw (the crude extract of poppy straw in either liquid, solid or
 39 powder form which contains the phenanthrene alkaloids of the opium poppy).

40 (c) *Opiates.* -- Unless specifically excepted or unless in another schedule, any of the
41 following opiates, including its isomers, esters, ethers, salts and salts of isomers, esters and
42 ethers whenever the existence of such isomers, esters, ethers and salts is possible within the
43 specific chemical designation, dextrorphan and levopropoxyphene excepted:

- 44 (1) Alfentanil;
- 45 (2) Alphaprodine;
- 46 (3) Anileridine;
- 47 (4) Bezitramide;
- 48 (5) Bulk dextropropoxyphene (nondosage forms);
- 49 (6) Carfentanil;
- 50 (7) Dihydrocodeine;
- 51 (8) Diphenoxylate;
- 52 (9) Fentanyl;
- 53 (10) Isomethadone;
- 54 (11) Levo-alphacetylmethadol; some other names: levo-alpha-acetylmethadol,
- 55 levomethadyl acetate, LAAM;
- 56 (12) Levomethorphan;
- 57 (13) Levorphanol;
- 58 (14) Metazocine;
- 59 (15) Methadone;
- 60 (16) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane;
- 61 (17) Moramide-Intermediate, 2-methyl-3-morpholino-1,

2018R2250

- 62 1-diphenylpropane-carboxylic acid;
- 63 (18) Pethidine; (meperidine);
- 64 (19) Pethidine-Intermediate-A, 4-cyano-1-methyl-4- phenylpiperidine;
- 65 (20) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;
- 66 (21) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
- 67 (22) Phenazocine;
- 68 (23) Piminodine;
- 69 (24) Racemethorphan;
- 70 (25) Racemorphan;
- 71 (26) Remifentanil;

72 (27) Sufentanil;

73 (28) Tapentadol

74 (29) Thiafentanil (4-(methoxycarbonyl)-4-(N-phenmethoxyacetamido)-1-275 (thienyl)ethylpiperidine), including its isomers, esters, ethers, salts and salts of isomers, esters
76 and ethers.

(d) *Stimulants.* -- Unless specifically excepted or unless listed in another schedule, any
material, compound, mixture or preparation which contains any quantity of the following
substances having a stimulant effect on the central nervous system:

80 (1) Amphetamine, its salts, optical isomers and salts of its optical isomers;

- 81 (2) Methamphetamine, its salts, isomers and salts of its isomers;
- 82 (3) Methylphenidate;
- 83 (4) Phenmetrazine and its salts; and
- 84 (5) Lisdexamfetamine.

(e) *Depressants.* -- Unless specifically excepted or unless listed in another schedule, any
material, compound, mixture or preparation which contains any quantity of the following
substances having a depressant effect on the central nervous system, including its salts, isomers

- 88 and salts of isomers whenever the existence of such salts, isomers and salts of isomers is
- 89 possible within the specific chemical designation:
- 90 (1) Amobarbital;
- 91 (2) Glutethimide;
- 92 (3) Pentobarbital;
- 93 (4) Phencyclidine;
- 94 (5) Secobarbital.
- 95 (f) Hallucinogenic substances:
- 96 Dronabinol [(-)-delta-9-trans tetrahydrocannabinol] if in an FDA approved oral solution
- 97 Nabilone: [Another name for nabilone: (+-)-trans-3-(1, 1-dimethylheptyl)-6, 6a, 7, 8, 10,

98 10a-hexahydro-1-hydroxy-6, 6-dimethyl-9H-dibenzo [b,d] pyran-9-one].

- 99 (g) Immediate precursors. -- Unless specifically excepted or unless listed in another
- schedule, any material, compound, mixture, or preparation which contains any quantity of the
- 101 following substances:
- 102 (1) Immediate precursor to amphetamine and methamphetamine:
- 103 (A) Phenylacetone;
- 104 (B) Some trade or other names: phenyl-2-propanone; P2P; benzyl methyl ketone; methyl
- 105 benzyl ketone;
- 106 (2) Immediate precursors to phencyclidine (PCP):
- 107 (A) 1-phenylcyclohexylamine; and
- 108 (B) 1-piperidinocyclohexanecarbonitrile (PCC).
- 109 (3) Immediate precursor to fentanyl:
- 110 4-anilino-N-phenethyl-4-piperidine (ANPP).

§60A-2-210. Schedule IV.

- 1 (a) Schedule IV shall consist of the drugs and other substances, by whatever official name,
- 2 common or usual name, chemical name, or brand name designated, listed in this section.

3	(b) Narcotic drugs. — Unless specifically excepted or unless listed in another schedule,
4	any material, compound, mixture or preparation containing any of the following narcotic drugs, or
5	their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth
6	below:
7	(1) Not more than 1 milligram of difenoxin and not less than 25 micrograms of atropine
8	sulfate per dosage unit;
9	(2) Dextropropoxyphene (alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2-
10	propionoxybutane).
11	(c) Depressants. — Unless specifically excepted or unless listed in another schedule, any
12	material, compound, mixture or preparation which contains any quantity of the following
13	substances, including its salts, isomers and salts of isomers whenever the existence of such salts,
14	isomers and salts of isomers is possible within the specific chemical designation:
15	(1) Alprazolam;
16	(2) Barbital;
17	(3) Bromazepam;
18	(4) Camazepam;
19	(5) Carisoprodol;
20	(6) Chloral betaine;
21	(7) Chloral hydrate;
22	(8) Chlordiazepoxide;
23	(9) Clobazam;
24	(10) Clonazepam;
25	(11) Clorazepate;
26	(12) Clotiazepam;
27	(13) Cloxazolam;
28	(14) Delorazepam;

- 29 (15) Diazepam;
- 30 (16) Dichloralphenazone;
- 31 (17) Estazolam;
- 32 (18) Ethchlorvynol;
- 33 (19) Ethinamate;
- 34 (20) Ethyl loflazepate;
- 35 (21) Fludiazepam;
- 36 (22) Flunitrazepam;
- 37 (23) Flurazepam;
- 38 (24) Fospropofol;
- 39 (25) Halazepam;
- 40 (26) Haloxazolam;
- 41 (27) Ketazolam;
- 42 (28) Loprazolam;
- 43 (29) Lorazepam;
- 44 (30) Lormetazepam;
- 45 (31) Mebutamate;
- 46 (32) Medazepam;
- 47 (33) Meprobamate;
- 48 (34) Methohexital;
- 49 (35) Methylphenobarbital (mephobarbital);
- 50 (36) Midazolam;
- 51 (37) Nimetazepam;
- 52 (38) Nitrazepam;
- 53 (39) Nordiazepam;
- 54 (40) Oxazepam;

- 55 (41) Oxazolam;
- 56 (42) Paraldehyde;
- 57 (43) Petrichloral;
- 58 (44) Phenobarbital;
- 59 (45) Pinazepam;
- 60 (46) Prazepam;
- 61 (47) Quazepam;
- 62 (48) Temazepam;
- 63 (49) Tetrazepam;
- 64 (50) Triazolam;
- 65 (51) Zaleplon;
- 66 (52) Zolpidem;
- 67 (53) Zopiclone'

68 (54) Suvorexant ([(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl] [5-69 methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone).

(d) Any material, compound, mixture or preparation which contains any quantity of the
following substance, including its salts, isomers (whether optical, position or geometric) and salts
of such isomers whenever the existence of such salts, isomers and salts of isomers is possible:
Fenfluramine and Dexfenfluramine.

(e) *Stimulants.* — Unless specifically excepted or unless listed in another schedule, any
material, compound, mixture or preparation which contains any quantity of the following
substances having a stimulant effect on the central nervous system, including its salts, isomers
and salts of isomers:

78 (1) Cathine ((+)-norpseudoephedrine);

79 (2) Diethylpropion;

80 (3) Fencamfamin;

2018R2250

- 81 (4) Fenproporex;
- 82 (5) Mazindol;
- 83 (6) Mefenorex;
- 84 (7) Modafinil;
- 85 (8) Pemoline (including organometallic complexes and chelates thereof);
- 86 (9) Phentermine;
- 87 (10) Pipradrol;
- 88 (11) Sibutramine;
- 89 (12) SPA ((-)-1-dimethylamino-1,2-diphenylethane);

90 (13) Eluxadoline (5-[[(2S)-2-amino-3-[4-aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl

91 [(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic acid);

92 (f) Other substances. — Unless specifically excepted or unless listed in another schedule,

any material, compound, mixture or preparation which contains any quantity of the following
substances, including its salts:

95 (1) Pentazocine;

96 (2) Butorphanol.

97 (3) Tramadol (2-[(dimethylamino)methyl]-1-(3-methoxyphenyl) cyclohexanol);

Amyl nitrite, butyl nitrite, isobutyl nitrite and the other organic nitrites are controlled substances and no product containing these compounds as a significant component shall be possessed, bought or sold other than pursuant to a bona fide prescription or for industrial or manufacturing purposes.

§60A-2-212. Schedule V.

(a) Schedule V shall consist of the drugs and other substances, by whatever official name,
 common or usual name, chemical name, or brand name designated, listed in this section. <u>Unless</u>
 <u>specifically excepted or unless listed in another schedule, any material, compound, mixture or</u>
 preparation which contains any quantity of the following substances, including its salts.

2018R2250

5 (b) Narcotic drugs containing nonnarcotic active medicinal ingredients. Any compound, 6 mixture or preparation containing any of the following narcotic drugs or their salts calculated as 7 the free anhydrous base or alkaloid in limited quantities as set forth below, which shall include 8 one or more nonnarcotic active medicinal ingredients in sufficient proportion to confer upon the 9 compound, mixture or preparation valuable medicinal qualities other than those possessed by the 10 narcotic drug alone.:

11 (1) Not more than 200 milligrams of codeine per 100 milliliters or per 100 grams;

12 (2) Not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams;

13 (3) Not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 grams;

14 (4) Not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of
 15 atropine sulfate per dosage unit;

16 (5) Not more than 100 milligrams of opium per 100 milliliters or per 100 grams;

17 (6) Not more than 0.5 milligrams of difenoxin and not less than 25 micrograms of atropine
 18 sulfate per dosage unit.

(c) Stimulants: — Unless specifically exempted or excluded or unless listed in another
 schedule, any material, compound, mixture or preparation which contains any quantity of the
 following substances having a stimulant effect on the central nervous system, including its salts,
 isomers and salts of isomers:

23 (1) Pyrovalerone.

(d) Any compound, mixture or preparation containing as its single active ingredient
ephedrine, pseudoephedrine or phenylpropanolamine, their salts or optical isomers, or salts of
optical isomers except products which are for pediatric use primarily intended for administration
to children under the age of 12: *Provided*, That neither the offenses set forth in section four
hundred one, article four of this chapter, nor the penalties therein, shall be applicable to ephedrine,
pseudoephedrine or phenylpropanolamine which shall be subject to the provisions of article ten
of this chapter.

31	(e) Depressants: — Unless specifically exempted or excluded or unless listed in another
32	schedule, any material, compound, mixture or preparation which contains any quantity of the
33	following substances having a depressant effect on the central nervous system, including its salts:
34	(1) Ezogabine [N-[2-amino-4-94-fluorobenzylamino)-phenyl]-carbamic acid ethyl ester];
35	(2) Lacosamide [(R)-2-acetoamido- N -benzyl-3-methoxy-propionamide];
36	(3) Pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic acid]; and
37	(4) Brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide) (also referred to
38	as BRV; UCB-34714; Briviact), including its salts.
39	(f) Other substances:
40	(1) Gabapentin
41	(2) Pregabalin
42	(3) Tramadol (2-[(dimethylamino)methyl]-1-(3-methoxyphenyl) cyclohexanol).

NOTE: The purpose of this bill is to update the schedule of controlled substances.

Strike-throughs indicate language that would be stricken from a heading or the present law and underscoring indicates new language that would be added.